30 closest matches · ranked by relevance
Kawasaki Disease
Primary: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion — 11; 11…
Mucocutaneous Lymph Node Syndrome
Primary: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. — 25; 40 Participants
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Primary: Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration — 75.0; 33.3 percentage of patients
Kawasaki Disease
Primary: Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) — 2; 3 events
Kawasaki Disease
Primary: Number of Participants With Adverse Events — 2; 3; 13 participants
Mucocutaneous Lymph Node Syndrome · Kawasaki Disease
Primary: IVIG Refractory — 13; 22 Participants — p=.10
Kawasaki Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Multisystem Inflammatory Syndrome-Children
Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants
Kawasaki Disease
Primary: Number of Participants With SAE — 4 Participants
Wegener's Granulomatosis
Primary: Remission of Vasculitis — 95 Percentage of participants
Kawasaki Disease
Primary: Determine the Predictive Value of Cardiolite® Rest and Stress MPI to Define Pediatric Populations With Kawasaki Disease at High and Low Risk of Developing Cardiac…
Granulomatosis With Polyangiitis
Primary: Percentage of Participants With Adverse Events (AEs), Including Serious AEs — 100; 100; 28; 48 percentage of participants
Graft Versus Host Disease
Primary: Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide — 4; 4; 2 Participants
Antibody Mediated Rejection of Kidney Transplant
Primary: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) — 1 Participants
Relapsing Polychondritis
Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm
JIA Associated Uveitis
Primary: Number of Participants Reported as Complete Responders to Golimumab — 8 Participants
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Hyperbilirubinemia · Erythroblastosis, Fetal
Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765
Primary Immunodeficiency Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs — 12; 3; 12 Participants
Graft Versus Host Disease
Primary: Number of Participants Experiencing Treatment Success — 8 Participants
End Stage Renal Disease
Primary: Number of Patients That Underwent Transplantation — 32 Participants
Primary Immunodeficiency Disease
Primary: Incidence Rate of Acute Serious Bacterial Infections (ABSIs) — 0.0; 0.0 infections per participant-year
Obsessive-Compulsive Disorder · Children · Anxiety Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale Total Score — 20.59; 25.67 units on a scale — p=0.44
Graft vs Host Disease
Primary: Phase I: MTD (USP hCG) — 2000; 2000; 5000 Pregnyl dosage (USP hCG)
Miscarriage, Recurrent · Abortion, Habitual
Primary: Number of Successful Pregnancies Defined as an Ongoing Pregnancy Over 20 Weeks Gestation, Per Number of Index Pregnancies — 16; 15 Successful pregnancies — p=<0.05
Juvenile Idiopathic Arthritis
Primary: Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16 — 90.0 percentage of participants
Rheumatoid Arthritis
Primary: Change From Baseline in DAS28 Score at Week 24 — -2.12 scores on a scale
Myositis · Dermatomyositis · Polymyositis
Primary: Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients — 20.2; 20.0 Weeks — p==0.74
Anterior Uveitis · Arthritis, Juvenile Idiopathic · Iritis
Primary: Number of Participants With a Two-step Reduction in Inflammation — 5 participants
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035